

10-01-01

Box 50

Docket No. D0039NP

Express Mail No. EL 912004928 US

23914
PATENT TRADEMARK OFFICE

JJC978 U.S. PTO
00/066150

09/26/01

↑AFFIX CUSTOMER NO. LABEL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
UTILITY APPLICATION AND FEE TRANSMITTAL §(1.53(b))

Commissioner for Patents
BOX PATENT APPLICATION
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the patent application of

Inventor(s) names and addresses:

(1) John N. Feder
277 Dutchtown Zion Road
Belle Mead, NJ 08502
United States of America

(2) Gabe Mintier
318 Morrison Avenue
Hightstown, NJ 08520
United States of America

Additional inventors are listed on a separate sheet

For: A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR, HGPRBMY4, EXPRESSED HIGHLY IN PROSTATE, COLON, AND LUNG

Enclosed Are:

115 page(s) of specification

1 page(s) of Abstract

6 page(s) of claims

12 sheets of Formal Informal drawings

____ page(s) of Declaration and Power of Attorney

- Unsigned
- Newly Executed
- Copy from prior application
- Deletion of inventors including Signed Statement under 37 C.F.R. §1.63(d)(2)

REQUEST AND CERTIFICATION UNDER 35 U.S.C. §122(b)(2)(B)(i) (form PTO/SB/25)

FTO/SB/SS
As indicated on the attached Request and Certification, Applicant(s) certify that the invention disclosed in the attached application HAS NOT and WILL NOT be the subject of an application filed in another country, or under a multilateral agreement, that

requires publication at eighteen months after filing. Applicant(s) therefore request(s) that the attached application NOT be published under 35 U.S.C. §122(b).

Incorporation by Reference:
 The entire disclosure of the prior application, from which a copy of the combined Declaration and Power of Attorney is supplied herein, is considered as being part of the disclosure of the accompanying application and is incorporated herein by reference.

Deletion of Inventors (37 C.F.R. §1.63(d) and §1.33(b))
Signed statement attached deleting inventor(s) named in the prior application serial no. ____, filed ____.

Microfiche Computer Program (Appendix)
31 page(s) of Sequence Listing
 computer readable disk containing Sequence Listing
 Statement under 37 C.F.R. §1.821(f) that computer and paper copies of the Sequence Listing are the same

Assignment Papers (assignment cover sheet and assignment documents)
 A check in the amount of \$40.00 for recording the Assignment
 Charge the Assignment Recordation Fee to Deposit Account No. 13-4500, Order No. ____.
 Assignment Papers filed in the parent application Serial No. ____.

Certification of chain of title pursuant to 37 C.F.R. §3.73(b)

Priority is claimed under 35 U.S.C. §119 for:
Application No(s). ____ , filed ____ , in ____ (country).
 Certified Copy of Priority Document(s) [____]
 filed herewith
 filed in application Serial No. ____ , filed ____ .

English translation document(s) [____]
 filed herewith
 filed in application Serial No. ____ , filed ____ .

Priority is claimed under 35 U.S.C. §119(e) for:
Provisional Application No. 60/313,202 filed August 17, 2001, Provisional Application No. 60/305,351 filed July 13, 2001, and Provisional Application No. 60/261,776 filed January 16, 2001, and Provisional Application No. 60/235,833 filed September 27, 2000.

Information Disclosure Statement
 Copy of [____] cited references
 PTO Form-1449
 References cited in parent application Serial No. ____ , filed ____ .

Related Case Statement under 37 C.F.R. §1.98(a)(2)(iii)

A copy of related pending U.S. Application(s) Serial No(s): _____, filed _____, respectively, is attached hereto.

A copy of related pending U.S. Application(s) entitled, _____, filed _____ to inventor(s) _____, respectively, is attached hereto.

A copy of each related application(s) was submitted in parent application serial no. _____, filed _____.

Preliminary Amendment

Return receipt postcard (MPEP 503)

This is a continuation divisional continuation-in-part of prior application serial no. _____, filed _____, to which priority under 35 U.S.C. §120 is claimed.

Cancel in this application original claims _____ of the parent application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

A Preliminary Amendment is enclosed. (Claims added by this Amendment have been properly numbered consecutively beginning with the number following the highest numbered original claim in the prior application).

A Petition for Extension of Time and a Fee therefor has been or is being filed in the parent application to extend the term for action in the parent application until _____.

A copy of the Petition for Extension of Time in the co-pending parent application is attached.

No Petition for Extension of Time and Fee therefor are necessary in the co-pending parent application.

Please abandon the parent application at a time while the parent application is pending or at a time when the petition for extension of time in that application is granted and while this application is pending has been granted a filing date, so as to make this application co-pending.

Transfer the drawing(s) from the parent application to this application

Amend the specification by inserting before the first line the sentence:
This is a continuation divisional continuation-in-part of co-pending application Serial No. _____, filed _____.

I. CALCULATION OF APPLICATION FEE				
	Number Filed	Number Extra	Rate	Basic Fee
Total Claims	41- 20 =	21	\$18.00/ \$9.00	\$ 378.00
Independent Claims	4- 3 =	1	\$80.00/ \$40.00	\$ 80.00
<input checked="" type="checkbox"/> Multiple Dependent Claims	If marked, add fee of \$270.00 (\$135.00)			\$ 270.00
			TOTAL:	\$1,438.00

Small entity status is or has been claimed. Reduced fees under 37 C.F.R. §1.9 (f) paid herewith
\$ ____.

A check in the amount of \$1,438.00 in payment of the application filing fees is attached.

Charge fee to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

The Commissioner is hereby authorized to charge any additional fees which may be required for filing this application pursuant to 37 CFR §1.16, **including all extension of time fees pursuant to 37 C.F.R. § 1.17 for maintaining copendency** with the parent application, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3053-4117US3. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: September 26, 2001

By: Leslie Serunian
Leslie A. Serunian
Registration No. 35,353

Sender's Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

Correspondence Address:

BRISTOL-MYERS SQUIBB COMPANY
Route 206 and Provinceline Road
Princeton, NJ 08540

Additional Inventors:

(3) Chandra S. Ramanathan
41 Alison Avenue
Wallingford, CT 06492
United States of America

(4) Donald R. Hawken
3223 Fieldcrest Court
Lawrenceville, NJ 08648
United States of America

(5) Angela Cacace
47 Silverbirch Lane
Clinton, CT 06413
United States of America

(6) Lauren Barber
561 Taylor Hill Road
Griswold, CT 06351
United States of America

(7) Michael G. Kornacker
17 Maclean Street
Princeton, NJ 08542
United States of America

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : FEDER, J. et al. Group Art Unit: To Be Assigned
Serial No. : To be Assigned Examiner: To Be Assigned
Filed : September 26, 2001
For : A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR, HGPRBMY4,
EXPRESSED HIGHLY IN PROSTATE, COLON, AND LUNG

EXPRESS MAIL CERTIFICATEExpress Mail Label No. EL 912004928 USDate of Deposit September 26, 2001

I hereby certify that the following attached paper(s) or fee


1. Utility Application and Fee Transmittal (1.53(b));
2. Specification (115 pages); claims (number of claims: 34 - 6 pages), Abstract (1 page), Drawings (12 sheets formal drawings - Figures 1-14);
3. Paper Copy of Sequence Listing (31 pages);
4. 1 computer disk containing Sequence Listing;
5. Statement Under 37 C.F.R. §1.821(f);
6. Check in the amount of \$1,438.00; and
7. Return Postcard.

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37

C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, BOX PATENT

APPLICATION, Washington, D.C. 20231.

Jesus R. Remedios
(Typed or printed name of person mailing
paper(s) or fee)


(Signature of person mailing paper(s) or fee)**Sender's Address:**

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

Correspondence Address:

BRISTOL-MYERS SQUIBB COMPANY
Route 206 and Provinceline Road
Princeton, NJ 08540

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : FEDER, J. et al.

Serial No. : To be assigned Group Unit : To be assigned

Filed : September 26, 2001 Examiner : To be assigned.

For : A NOVEL HUMAN G-PROTEIN COUPLED RECEPTOR,
HGPRBMY4, EXPRESSED HIGHLY IN PROSTATE, COLON
AND LUNGStatement Under 37 C.F.R. §1.821(f) or §1.825(b)Commissioner of Patents
Washington, D.C. 20231

Dear Sir:


I hereby certify that:

The paper Sequence Listing submitted herewith and computer readable Sequence Listing attached hereto are identical (37 C.F.R. §1.821(f)).

The substitute paper Sequence Listing and substitute computer readable Sequence Listing submitted herewith are identical. No new matter is included (37 C.F.R. §1.825(b)).

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Date: September 26, 2001By: 
Leslie A. Serunian
Reg. No. 35,353Sender's Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile

Correspondence Address:

BRISTOL-MYERS SQUIBB COMPANY
Route 206 and Provinceline Road
Princeton, NJ 08540